DOCSLIB.ORG

Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines COVID-19 Treatment Guidelines Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Credit NIAID-RML Downloaded from https://www.covid19treatmentguidelines.nih.gov/ on 9/25/2021 Visit https://www.covid19treatmentguidelines.nih.gov/ to access the most up-to-date guideline. How to Cite the COVID-19 Treatment Guidelines: COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed [insert date]. The COVID-19 Treatment Guidelines Panel regularly updates the recommendations in these guidelines as new information on the management of COVID-19 becomes available. The most recent version of the guidelines can be found on the COVID-19 Treatment Guidelines website (https://www.covid19treatmentguidelines.nih.gov/). Downloaded from https://www.covid19treatmentguidelines.nih.gov/ on 9/25/2021 Table of Contents What’s New in the Guidelines .................................................................................................. 5 The COVID-19 Treatment Guidelines Panel’s Statement on Bamlanivimab Plus Etesevimab for the Treatment of Mild to Moderate COVID-19 in Nonhospitalized Patients ..... 8 The COVID-19 Treatment Guidelines Panel’s Statement on the Prioritization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment or Prevention of SARS-CoV-2 Infection When There Are Logistical Constraints ...................................................................... 9 The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Casirivimab Plus Imdevimab as Post-Exposure Prophylaxis for SARS-CoV-2 Infection ... 10 Introduction ............................................................................................................................ 14 Overview of COVID-19 ........................................................................................................... 17 Testing for SARS-CoV-2 Infection ...................................................................................... 22 Prevention and Prophylaxis of SARS-CoV-2 Infection ...................................................... 28 Clinical Spectrum of SARS-CoV-2 Infection ...................................................................... 39 Clinical Management Summary ............................................................................................. 47 General Management of Nonhospitalized Patients with Acute COVID-19 ........................ 50 Therapeutic Management of Nonhospitalized Adults With COVID-19 .............................. 57 Therapeutic Management of Hospitalized Adults With COVID-19 .................................... 62 Care of Critically Ill Adult Patients With COVID-19 ............................................................... 75 General Considerations ..................................................................................................... 77 Infection Control ................................................................................................................ 85 Hemodynamics .................................................................................................................. 88 Oxygenation and Ventilation .............................................................................................. 92 Acute Kidney Injury and Renal Replacement Therapy....................................................... 99 Pharmacologic Interventions ........................................................................................... 100 Extracorporeal Membrane Oxygenation .......................................................................... 101 Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19 . 103 Remdesivir ....................................................................................................................... 105 Table 2a. Remdesivir: Selected Clinical Data ............................................................. 108 Chloroquine or Hydroxychloroquine and/or Azithromycin ............................................... 114 Table 2b. Chloroquine or Hydroxychloroquine and/or Azithromycin: Selected Clinical Data ............................................................................................... 118 Ivermectin ........................................................................................................................ 128 Table 2c. Ivermectin: Selected Clinical Data .............................................................. 133 Lopinavir/Ritonavir and Other HIV Protease Inhibitors .................................................... 152 Nitazoxanide .................................................................................................................... 157 Table 2d. Nitazoxanide: Selected Clinical Data .......................................................... 159 Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19 ....................................................................... 162 COVID-19 Treatment Guidelines 2 Downloaded from https://www.covid19treatmentguidelines.nih.gov/ on 9/25/2021 Anti-SARS-CoV-2 Antibody Products ................................................................................. 166 Anti-SARS-CoV-2 Monoclonal Antibodies ....................................................................... 168 Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data ............. 177 Convalescent Plasma ...................................................................................................... 181 Table 3b. COVID-19 Convalescent Plasma: Selected Clinical Data ........................... 188 Immunoglobulins: SARS-CoV-2-Specific ........................................................................ 199 Table 3c. Characteristics of SARS-CoV-2 Antibody-Based Products Under Evaluation for the Treatment of COVID-19 ....................................................................... 200 Cell-Based Therapy Under Evaluation for the Treatment of COVID-19 ............................. 204 Immunomodulators Under Evaluation for the Treatment of COVID-19.............................. 207 Colchicine ........................................................................................................................ 208 Corticosteroids ................................................................................................................. 212 Table 4a. Systemic Corticosteroids: Selected Clinical Data ....................................... 219 Table 4b. Inhaled Corticosteroids: Selected Clinical Data .......................................... 230 Fluvoxamine ..................................................................................................................... 232 Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors ..................................... 235 Table 4c. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data ................................................................................................ 238 Immunoglobulins: Non-SARS-CoV-2-Specific ................................................................ 242 Interferons (Alfa, Beta) ..................................................................................................... 244 Interleukin-1 Inhibitors ..................................................................................................... 248 Interleukin-6 Inhibitors ..................................................................................................... 251 Table 4d. Interleukin-6 Inhibitors: Selected Clinical Data ........................................... 257 Kinase Inhibitors: Baricitinib and Other Janus Kinase Inhibitors, and Bruton’s Tyrosine Kinase Inhibitors ................................................................................................ 269 Table 4e. Characteristics of Immunomodulators Under Evaluation for the Treatment of COVID-19 .................................................................................................... 276 Antithrombotic Therapy in Patients with COVID-19 ........................................................... 289 Supplements ......................................................................................................................... 298 Vitamin C .......................................................................................................................... 299 Vitamin D .......................................................................................................................... 302 Zinc .................................................................................................................................. 304 Considerations for Certain Concomitant Medications in Patients with COVID-19 ........... 308 COVID-19 and Special Populations ..................................................................................... 314 Special Considerations in Pregnancy .............................................................................. 315 Special Considerations in Children .................................................................................. 320 Special Considerations in Adults and Children With Cancer ........................................... 331 Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Therapy Candidates, Donors, and Recipients .........................
Load more

Recommended publications
  • A Factor That Should Raise Awareness in the Practice of Pediatric Medicine: West Nile Virus
    Case Report / Olgu Sunumu DOI: 10.5578/ced.201813 • J Pediatr Inf 2018; 12(2): e70-e72 A Factor That Should Raise Awareness in the Practice of Pediatric Medicine: West Nile Virus Çocuk Hekimliği Pratiğinde Farkındalığın Artması Gereken Bir Etken; Batı Nil Virüsü Duygu Uç1, Tamer Çelik1, Derya Gönen1, Asena Sucu1, Can Celiloğlu1, Orkun Tolunay1, Ümit Çelik1 1 Clinics of Pediatrics, Adana City Training and Research Hospital, Adana, Turkey Abstract Özet West Nile virus is an RNA virus found in Flaviviridae family and its vector Batı Nil virüsü Flaviviridae ailesinde yer alan bir RNA virüsü olup, vektörü is of Culex-type mosquitoes and the population of these flies soar dra- Culex türü sivrisineklerdir. Culex türü sineklerin popülasyonu Ağustos matically in August. Most of the infected people who have mild viremia ayında pik yapmaktadır. Ilımlı viremiye sahip enfekte bireylerin çoğu experience this disease asymptomatically or encounter situations simi- hastalığı asemptomatik geçirmekte ya da diğer viral enfeksiyonlara ben- lar to other viral infections. Patients suffer from fatigue, fever, and head- zeyen tablolarla karşımıza gelmektedir. Hastalarda sıklıkla halsizlik, ateş, ache, pain in the eyes, myalgia, diarrhea, vomiting, arthralgia, rash and baş ağrısı, gözlerde ağrı, miyalji, ishal, kusma, artralji, döküntü ve lenfa- lymphadenopathy. Similar to many diseases transmitted through mos- denopati görülebilmektedir. Sivrisinekler aracılığı ile bulaşan birçok has- quitoes, the West Nile virus should also be considered as a problem of talık
    [Show full text]
  • The Epidemiology of COVID-19 in Canada in 2020: the Pre-Vaccine Era February 2021
    The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era February 2021 An RSC Policy Briefing The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era An RSC Policy Briefing Authors Wendy Sligl (Chair) University of Alberta David Waldner University of Alberta Jennie Johnstone University of Toronto Robyn Harrison University of Alberta Duncan Webster Dalhousie University Lynora Saxinger University of Alberta Peer Review Monitor Tom Marrie, FRSC Dalhousie University Peer Reviewers Nick Daneman University of Toronto Rob Fowler University of Toronto Srinivas Murthy The University of British Columbia David Patrick The University of British Columbia Dan Reid Dalhousie University Robert Strang Chief Medical Officer of Health, Nova Scotia Suggested citation for Policy Briefing Report: Waldner D, Harrison R, Johnstone J, Saxinger L, Webster D, Sligl W. The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era. Royal Society of Canada. 2021 Cover Art Christine De Vuono, For Your Own Good, (2020) Over the course of the pandemic, those in long term care facilities have been hit hardest with the impact of COVID-19 outbreaks. The response has been to lock down care homes and ban visitors, volunteers and even care packages, as attempts to stop the virus from entering the facility. This had the unintended, but very real consequence of isolating our most vulnerable from those who care for and love them. “For Your Own Good”, made of 100 carved figures from identical bars of soap, then placed in mason jars, which in turn are placed on shelves, allow us to look in on the miniature elderly figures, who look out at us.
    [Show full text]
  • (MGH) COVID-19 Treatment Guidance
    Version 8.0 4/28/2021 10:00AM © Copyright 2020 The General Hospital Corporation. All Rights Reserved. Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance This document was prepared (in March, 2020-April, 2021) by and for MGH medical professionals (a.k.a. clinicians, care givers) and is being made available publicly for informational purposes only, in the context of a public health emergency related to COVID-19 (a.k.a. the coronavirus) and in connection with the state of emergency declared by the Governor of the Commonwealth of Massachusetts and the President of the United States. It is neither an attempt to substitute for the practice of medicine nor as a substitute for the provision of any medical professional services. Furthermore, the content is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment. The information herein should be adapted to each specific patient based on the treating medical professional’s independent professional judgment and consideration of the patient’s needs, the resources available at the location from where the medical professional services are being provided (e.g., healthcare institution, ambulatory clinic, physician’s office, etc.), and any other unique circumstances. This information should not be used to replace, substitute for, or overrule a qualified medical professional’s judgment. This website may contain third party materials and/or links to third party materials and third party websites for your information and convenience. Partners is not responsible for the availability, accuracy, or content of any of those third party materials or websites nor does it endorse them.
    [Show full text]
  • Celebrating 100 Years
    AMERICANa CERAMICting SOCIETY ars Celebr 100 ye bulletinemerging ceramics & glass technology JUNE/JULY 2021 Student perspectives on facing uncertainty New issue inside: JUNE/JULY 2021 • VOLUME 2 • ISSUE 2 www.ceramics.org/ceramicandglassmanufacturing PREPARING FOR CONTINGENCIES HELPED COMPANIES GROW DURING THE PANDEMIC THE ROCKY ROAD BACK TO ‘LIVE’: IMPACT OF THE PANDEMIC FROM A TRADE SHOW PERSPECTIVE Materials Genome Initiative at 10 years | 2021-2022 ACerS Board members and directors When it Comes to Heat, We Sweat the Details! Your firing needs are unique. Our laboratory can run tests to So why use an “off the shelf” help identify your process kiln in your process? boundaries. Through our toll firing facility, we can At Harrop, we get it. help to further define That’s why, for over a the equipment/ century, we’ve been processing putting in the hard work combination that to design and service works best for your custom kilns. Is it harder material. And if you to do things this way? are not ready for a Yes. Is the extra effort new kiln, we can toll worth it? You bet! fire your material to help meet your At Harrop, we don’t production needs. stop there. If you aren’t sure what you Does your current need, we can help. kiln company sweat the details? www.harropusa.com 1.614.231.3621 Harrop Ad Sweat the Details ACerS Full Size w 100 logo.indd 1 5/21/20 9:33 AM contents June/July 2021 • Vol. 100 No.5 feature articles department News & Trends . 3 Materials Genome Initiative 10 years later: Spotlight .
    [Show full text]
  • Effectiveness of Bnt162b2 and Mrna-1273 Covid-19 Vaccines BMJ: First Published As 10.1136/Bmj.N1943 on 20 August 2021
    RESEARCH Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines BMJ: first published as 10.1136/bmj.n1943 on 20 August 2021. Downloaded from against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study Hannah Chung,1 Siyi He,1 Sharifa Nasreen,1 Maria E Sundaram,1,2 Sarah A Buchan,1,2,3,4 Sarah E Wilson,1,2,3,4 Branson Chen,1 Andrew Calzavara,1 Deshayne B Fell,1,5,6 Peter C Austin,1,7 Kumanan Wilson,5,8,9 Kevin L Schwartz,1,2,3 Kevin A Brown, 1,2,3 Jonathan B Gubbay,3,10 Nicole E Basta,11 Salaheddin M Mahmud,12 Christiaan H Righolt,12 Lawrence W Svenson,13,14,15,16 Shannon E MacDonald,15,17 Naveed Z Janjua,18,19 Mina Tadrous,1,20,21 Jeffrey C Kwong,1,2,3,4,22,23 on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators For numbered affiliations see ABSTRACT received at least one dose of vaccine. Among end of the article OBJECTIVE participants who tested positive, 2479 (4.7%) were Correspondence to: J Kwong To estimate the effectiveness of mRNA covid-19 admitted to hospital or died. Vaccine effectiveness [email protected] vaccines against symptomatic infection and severe against symptomatic infection observed ≥14 days (or @DrJeffKwong on Twitter ORCID 0000-0002-7820-2046) outcomes (hospital admission or death). after one dose was 60% (95% confidence interval Additional material is published DESIGN 57% to 64%), increasing from 48% (41% to 54%) at online only.
    [Show full text]
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • Familial Mediterranean Fever
    :: Familial Mediterranean fever – This document is a translation of the French recommendations drafted by Prof Gilles Grateau, Dr Véronique Hentgen, Dr Katia Stankovic Stojanovic and Dr Gilles Bagou reviewed and published by Orphanet in 2010. – Some of the procedures mentioned, particularly drug treatments, may not be validated in the country where you practice. Synonyms: Periodic disease, FMF Definition: Familial Mediterranean fever (FMF) is an auto-inflammatory disease of genetic origin, affecting Mediterranean populations and characterised by recurrent attacks of fever accompanied by polyserositis that causes the symptoms. Colchicine is the basic reference treatment and is designed to tackle inflammatory attacks and prevent amyloidosis, the most severe complication of FMF. Further information: See the Orphanet abstract http://www.orpha.net/data/patho/Pro/en/Emergency_FamilialMediterraneanFever-enPro920.pdf ©Orphanet UK 1/5 Pre-hospital emergency care recommendations Call for a patient suffering from Familial mediterranean fever Synonyms periodic disease FMF Mechanisms auto-inflammatory disease that affects Mediterranean populations in particular, due to mutation of the MEFV gene that codes pyrin or marenostrin, this being the underlying cause of congenital immune dysfunction; repeated inflammatory attacks can lead to amyloidosis, particularly renal Specific risks in emergency situations acute inflammatory attack, particularly abdominal (pseudo-surgical), but also thoracic, articular (knees) or testicular fever as an expression
    [Show full text]
  • Impact of SARS-Cov-2 Variant on the Severity of Maternal Infection and Perinatal Outcomes: Data from the UK Obstetric Surveillan
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.22.21261000; this version posted July 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort. Nicola Vousden PhD1, Rema Ramakrishnan PhD1, Kathryn Bunch MA1, Edward Morris MD2, Nigel Simpson MBBS3, Christopher Gale PhD4, Patrick O’Brien MBBCh,2,5, Maria Quigley MSc1, Peter Brocklehurst MSc6, Jennifer J Kurinczuk MD1, Marian Knight DPhil1 1National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK 2Royal College of Obstetricians and Gynaecologists, London, UK 3Department of Women's and Children's Health, School of Medicine, University of Leeds, UK 4Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, London, UK 5Institute for Women’s Health, University College London, London, UK 6Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, UK *Corresponding author: Marian Knight National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK 01865 289700 [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.07.22.21261000; this version posted July 25, 2021.
    [Show full text]
  • Aids for Management of Common Headache Disorders in Primary Care
    J Headache Pain (2007) 8:S1 DOI 10.1007/s10194-007-0366-y Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide in collaboration with European Headache Federation Aids for management of common headache disorders in primary care This is a "Springer Open Choice" article. Unrestricted non-commercial use, distribution, and reproduction in any medium is permitted, provided the original author and source are credited. J Headache Pain (2007) 8:S2 PREFACE T.J. Steiner Aids for management of common headache P. Martelletti disorders in primary care T.J. Steiner Medical management of headache Whilst the focus of this publication Chairman: Global Campaign Committee disorders, for the vast majority of is Europe, these management aids Lifting The Burden people affected by them, can and have been developed to be useful should be carried out in primary cross-culturally and may suit a P. Martelletti care. It does not require specialist wider population. Editor-in-Chief Journal of Headache and Pain skills. Nonetheless, it is recognised The European principles of that non-specialists throughout management of common headache Europe may have received limited disorders in primary care are the training in the diagnosis and treat- essential core of these aids. These ment of headache. are set out in 12 sections, each one This special supplement of Journal more-or-less stand-alone. They are of Headache and Pain is the out- supplemented in Appendices 1 and put of a collaboration between the 2 by a measure of headache burden European Headache Federation (the HALT index), intended for (EHF) and Lifting The Burden: the pre-treatment assessment of illness Global Campaign to Reduce the severity, an outcome measure (the Burden of Headache Worldwide, a HART index), which is a guide to programme for the benefit of peo- follow-up and need for treatment- ple with headache conducted under review, and a series of patient the auspices of the World Health information leaflets developed to Organization.
    [Show full text]
  • An Examination of COVID-19 Medications' Effectiveness
    healthcare Review An Examination of COVID-19 Medications’ Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review Mahmoud Al-Masaeed 1,* , Mohammad Alghawanmeh 2, Ashraf Al-Singlawi 3 , Rawan Alsababha 4 and Muhammad Alqudah 1 1 Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia; [email protected] 2 Faculty of Pharmacy, Philadelphia University, Amman 19392, Jordan; [email protected] 3 Independent Scholar, Amman 11731, Jordan; [email protected] 4 School of nursing and Midwifery, Western Sydney University, Sydney 2560, Australia; [email protected] * Correspondence: [email protected] Abstract: Background: The review seeks to shed light on the administered and recommended COVID- 19 treatment medications through an evaluation of their efficacy. Methods: Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review’s literature search was guided by the WHO Citation: Al-Masaeed, M.; solidarity clinical trials for COVID-19 scope and trial-assessment parameters. Results: The findings Alghawanmeh, M.; Al-Singlawi, A.; indicate that the use of antiretroviral drugs as an early treatment for COVID-19 patients has been Alsababha, R.; Alqudah, M. An useful. It has reduced hospital time, hastened the clinical cure period, delayed and reduced the Examination of COVID-19 need for mechanical and invasive ventilation, and reduced mortality rates. The use of vitamins, Medications’ Effectiveness in minerals, and supplements has been linked to increased immunity and thus offering the body a Managing and Treating COVID-19 fighting chance. Nevertheless, antibiotics do not correlate with improving patients’ wellbeing and Patients: A Comparative Review.
    [Show full text]
  • National Guidelines for Clinical Management of Chikungunya 2016
    CONTENTS Chapter Name of the Chapter Page No. 1 INTRODUCTION 1 2 Chikungunya: Status & disease burden 2-4 2.1 Transmission & trends 2 2.2 Global situation 2 2.3 Chikungunya in India (Past & present) 2-4 3 Laboratory diagnosis of Chikungunya f ever 5-7 3.1 Types of Laboratory tests available and specimens required: 5-6 3.2 Interpretation of results: 6 3.3 NVBDCP Laboratory Network: 6-7 3.4 Laboratory confirmation in case of Chikungunya outbreak 7 4 Case definition and differential diagnos is 8-9 4.1 Case definition 8 4.2 Differential diagnosis 8-9 5 Clinical manifestation of Chikungunya 10-16 5.1 Incubation period 10 5.2 Clinical Features: 10 5.3 Clinical Classification of severity of Chikungunya: 11 5.4 High Risk group: 11-12 5.5 Fever 12 5.6 Arthralgia 12 5.7 Back ache 12 5.8 Headache 13 5.9 Rash: 13 5.10 Stomatitis and oral ulcers : 13 5.11 Hyperpigmentation 13 5.12 Exfoliative dermatitis 13 5.13 Retrobulbar pain 13 5.14 Neurological manifestations 13 5.15 Occular manifestations 13 5.16 Chikungunya in Children 13-14 5.17 Impact of Chikungunya in Pregnancy & Neonates 14 5.17 Chikungunya in Elderly 14 5.18 Chikungunya Co infection with Dengue 14-15 5.19 Sequelae: 15 5.20 Mortality 15 5.21 Pathogenesis 16 6 Cl inical management of Chikungunya cases 17-20 6.1 Guiding principles of clinical management 17-18 6.2 Hospital based 18-19 6.3 Guiding principles for managing chronic pain 19 6.4 Summary 19-20 7 Public Health Measures 21-22 7.1 Minimizing transmissio n of infection: Annexure 1 Virus Genotype of Chikungunya virus 23-24 Vector Transmission Cycle References and Further study 25-26 Draft Chapter 1 INTRODUCTION Chikungunya fever is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes.
    [Show full text]
  • Disease(S) Brand Name Drug Name Drug Company Phone Number Website Calaspargase No Financial Assistance Offered at This Asparlas Servier Pegol-Mknl Time
    Co-Pay Assistance Resource Guide for Blood Cancer Patients Acute Lymphoblastic Leukemia (ALL) Disease(s) Brand Name Drug Name Drug Company Phone Number Website calaspargase No financial assistance offered at this Asparlas Servier pegol-mknl time. https://www.pfizertogether.com/hcp/bes BESPONSA Ozogamicin Wyeth 1-877-744-5675 ponsa/patient-financial-assistance Acute Lymphoblastic http://www.amgen.com/responsibility/ac Leukemia (ALL) - B- cess-to-medicine/reimbursement- Blincyto Blinatumomab Amgen 1-855-669-9360 cell Precursor support-services-and-financial- assistance-programs/ https://www.hcp.novartis.com/products/k Kymriah Tisagenlecleucel Novartis 1-844-459-6742 ymriah/acute-lymphoblastic-leukemia- children/access/ http://www.oncologyaccessnow.com/ind Gleevec® Imatinib Mesylate Novartis 1-800-282-7630 ex.jsp *not offering patient assistance nor cost savings program* Gleevec® Generic Imatinib Mesylate Teva 1-844-546-8639 https://www.tevagenerics.com/patients/fr Ph+ Acute equently-asked-questions/#q-1-1 Lymphoblastic Generic Imatinib Imatinib Mesylate Sun Pharma 1/844-502-5950 https://rxoutreach.org/ Leukemia (ALL) https://www.takedaoncology1point.com/ Iclusig® Ponatinib Takeda 1-844-817-6468 patient/financial-assistance Bristol-Myers Sprycel® Dasatinib 1-877-526-7334 https://www.sprycel.com/sprycel-assist Squibb Trisenox Arsenic Trioxide Teva 1-877-237-4881 http://www.tevacares.org/ http://www.amgen.com/responsibility/ac Acute Lymphoblastic cess-to-medicine/reimbursement- Leukemia (ALL) Blincyto Blinatumomab Amgen 1-855-669-9360 support-services-and-financial-
    [Show full text]